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Introduction: Endovascular and surgical strategies have been used to manage patients with thrombosed vascular access for
hemodialysis. We analyzed the evidence to see whether endovascular or surgical treatment has the best outcome in terms
of primary success rate and long-term patency.
Methods: We performed a systematic literature search of endovascular and surgical repair of thrombosed hemodialysis
vascular access. The analysis included meta-analysis, randomized, and population-based studies of thrombosed arterio-
venous fistulae and grafts.
Results: One meta-analysis and eight randomized studies on the treatment of arteriovenous graft thrombosis were
identified. Studies conducted before 2002 demonstrated a significantly better primary success rate and primary and
secondary patencies of surgical thrombectomy vs endovascular intervention. After 2002, similar results of both
techniques have been reported. Only population-based studies on the treatment of thrombosed autogenous arteriovenous
fistulae have been published, showing similar outcome of surgical and endovascular intervention in terms of primary
success. The long-term primary and secondary patencies are slightly better for surgical treatment, but this concerns only
forearm fistulae.
Conclusions: The outcome of endovascular and surgical intervention for thrombosed vascular access is comparable, in
particular for thrombosed prosthetic grafts. Surgical treatment of autogenous arteriovenous fistulae is likely to have
benefit compared with endovascular means. Definitive randomized trials are needed to provide the level 1 evidence to
resolve this latter issue. (J Vasc Surg 2009;50:953-6.)Functional vascular access is a prerequisite for adequate
hemodialysis treatment in patients with end-stage renal
disease (ESRD). The major drawback of vascular access is a
high incidence of thrombotic occlusion, caused by obstruc-
tive stenoses that are initiated by hyperplastic lesions of the
vessel intimal layer. Surgical or endovascular thrombus
removal and repair of stenotic lesions remains the major
goal toward access salvage and prolongation of patency
rate. The strategy to choose for endovascular or surgical
intervention remains obscure, however, and evidence from
the literature may possibly elucidate the potential benefits
and outcomes of both techniques.
METHODS
A systematic literature review from 1995 to 2009 using
a Medline search of English language publications was
performed. Keywords used were vascular access, hemodial-
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doi:10.1016/j.jvs.2009.06.058ysis, thrombosis, arteriovenous fistula, and arteriovenous
graft. For this review in particular, large population-based,
randomized, and meta-analysis studies were included.
Small patient studies and case reports were excluded. Be-
cause of potential differences in treatment methods and
outcomes in arteriovenous (AV) grafts and fistulae (AVF),
these types of access were analyzed separately.
RESULTS
We identified 78 studies. There were 42 studies on
endovascular (n 37) and surgical (n 5) intervention for
graft thrombosis, of which eight randomized studies com-
pared endovascular therapy vs surgery. One meta-analysis
on the treatment of AV graft thrombosis was identified.
There were 36 studies on autogenous fistulae thrombosis
treatment, either by surgery (n  6) or percutaneous
techniques (n 30). None of the studies on fistula throm-
bectomy were randomized. The studies on fistulae ap-
peared to be published more recently than the graft studies,
indicating the growing interest and strategy to create pre-
dominantly autogenous access in ESRD patients in the
United States and Europe.
The meta-analysis by Green et al1 published in 2002,
included seven randomized studies (1987-1999) compar-
ing surgical vs endovascular graft thrombectomy in terms
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tion of the relative risk and risk difference showed at all time
periods for the aggregated data a superiority of surgical
thrombectomy vs endovascular intervention. These differ-
ences can be mainly ascribed to the relatively low initial
technical success rate of endovascular thrombectomy of
76% vs 85% for surgical intervention. In the randomized
studies included in this meta-analysis, different techniques
for endovascular thrombectomy were used, comprising
pulse-spray infusion of urokinase,2 mechanical thrombec-
tomy,3,4 or a combination of both.5-7
More recently published studies, including a random-
ized study, showed markedly improved technical success
rates (mean, 92%; range 79%-100%) of endovascular inter-
vention for graft thrombosis. The randomized study by
Uflacker et al8 reported initial thrombectomy success rates
of 79% for endovascular and 77% for surgical treatment.
Graft patency at 30 and 90 days was 79% and 75% for the
endovascular and 73% and 68% for the surgically treated
patients (P  NS). The endovascular long-term patencies
seem to have improved compared with older studies. The
administration of tissue plasminogen activator (tPA),9 a
more potent thrombolytic agent, and the use of newer
thrombectomy devices10-12 may have contributed to this
better outcome of endovascular treatment (Table I).
The outcome of surgical treatment of thrombosed
grafts depends on whether additional graft revision with
patchplasty or graft interposition has been done. Without
additional graft revision, a dismal 1-year primary patency of
10% vs 27% for thrombectomy and additional revision has
been reported.13
Intervention studies on thrombosed autogenous AVF
have predominantly appeared after the year 2000. A few have
compared endovascular with surgical repair, but none was
randomized. The largest series is from Turmel-Rodrigues et
al14 and reports on 93 percutaneous declotting procedures in
73 patients with 56 forearm radiocephalic or ulnobasilic AVF
and 17 upper arm brachiocephalic or basilic AVF. Manual
thrombus aspiration with or without urokinase was applied,
and stents were only used on indication for resistant stenoses
or venous rupture. Technical success was higher in forearm
than upper arm AVF (93% vs 76% in upper arm AVF), and
1-year primary and secondary patencies were 49% and 81%,
Table I. Endovascular treatment of thrombosed grafts
First author, year No. Modality
Falk, 2001 62 Pulse-spray thrombolysis tPA
Sofocleous, 2002 68 Pulse-spray thrombolysis tPA
Cooper, 2003 17 Pulse-spray thrombolysis urok
Kolakovski, 2003 61 Percutaneous thrombectomy 
Uflacker, 2004 109 Mechanical thrombectomy
Bittl, 2005 105 Mechanical thrombectomy
Bakken, 2007 114 Pharmacomechanical thrombo
Kakkos, 2008 207 Mechanical thrombectomy
Lai, 2009 32 Mechanical thrombectomyrespectively (for upper arm AVF, 9% and 60%).Comparative results can be found in the literature with
usually a high technical success rate of 76% to 96%, al-
though low primary patencies of 18% to 70% are reported
with the need of multiple reinterventions to achieve accept-
able cumulative patencies15-18 (Table II). Upper arm AVF
do worse compared with forearm AVFs. Venous rupture
and arterial emboli are major complications and can usually
be treated by endovascular means with good results.
The outcome of surgical revision of thrombosed AVF is
summarized in Table III. The studies report thrombec-
tomy with or without patchplasty, but the creation of a
new, more proximally located AV anastomosis seems to be
particularly advantageous.19-21 The primary success rate of
this latter technique is 90% (range, 80%-100%), with high
1-year primary and secondary patencies of 74% and 87%,
respectively. Most studies on surgical thrombectomy of
AVF concern forearm accesses, and the results are compa-
rable with the outcome of endovascular treatment in terms
of primary success rate (90% vs 89%), but 1-year primary
(74% vs 40%) and secondary patency rates (87% vs 72%) are
higher.
DISCUSSION
Functional vascular access is of utmost importance for
the treatment of ESRD patients who need long-term inter-
mittent hemodialysis treatment. Timely intervention of a
thrombosed access is therefore mandatory to re-establish
the connection to the artificial kidney. The strategy of
whether to use surgical or endovascular means for this
purpose remains obscure. Evidence from the literature is
lacking and should be analyzed with caution. Implementa-
tion of guidelines has resulted in a shift from grafts towards
the use of autogenous fistulae for vascular access, particu-
larly in the United States. This feature can be noticed when
looking at the access issues that have been published.
Before 2002, numerous studies on endovascular and surgi-
cal intervention of thrombosed grafts were published,
whereas more recently, the treatment of thrombosed fistu-
lae in particular has been referenced.
The meta-analysis of randomized trials of endovascular
and surgical prosthetic graft intervention supports the use
of surgical techniques for graft thrombectomy.1 This could
be mainly attributed to the better initial success rate of
Technical success
Patency (1 yr)
Primary Secondary
92% 34% (6 mon) . . .
94% 44% (6 mon) 72% (6 mon)
94% 21% (4 mon) . . .
t . . . 8% 25%
79% 75% (3 mon) . . .
95% . . . 23%
95% . . . . . .
93% 29% 62%
94% 70% (3 mon) . . .inase
sten
lysissurgery. When looking into more detail at these studies,
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instance, different thrombectomy devices were used, rang-
ing from simple manual thromboaspiration by means of
Fogarty catheters, rotational devices to AngioJet rheolytic
catheters. Also, in some studies additional thrombolysis
with urokinase was performed. These differences in treat-
ment modalities make a fare comparison quite difficult.
One of the randomized studies was a multicenter study
with large differences in technical success rate (25% to
100%) between centers, indicating the lack of experience
with pharmacomechanical thrombectomy in some cen-
ters.4 In addition, the exact surgical procedure in most of
the studies was not defined, and it was unclear whether
completion angiography and repair of stenoses with patch-
plasty or graft interposition, or both, was performed. All
these issues may negatively influence the outcome of endo-
vascular as well as surgical techniques. Therefore, any rea-
sonable comparison between both techniques in a meta-
Table II. Endovascular treatment of thrombosed fistulae
First author, year No.
Location
AVF
Overbosch, 1996 24 24 forearm Mechanical t
Turmel-Rodrigues, 2000 73 56 forearm Thromboasp
17 upper arm
Haage, 2000 54 50 forearm Mechanical t
4 upper arm
Schon, 2000 20 . . . Mechanical t
Liang, 2002 42 37 forearm Angioplasty
5 upper arm
Rajan, 2002 25 19 forearm Mechanical t
6 upper arm
Bittl, 2005 39 . . . Mechanical t
Shatsky, 2005 62 24 forearm Thromboasp
36 upper arm
2 leg
Moossavi, 2007 49 23 forearm Mechanical t
26 upper arm
Jain, 2008 41 21 forearm Mechanical t
20 upper arm
Wu, 2009 48 48 forearm Mechanical t
tPA, Tissue plasminogen activator.
Table III. Surgical treatment of thrombosed fistulae
First author, year No.
Location
AVF M
Oakes. 1998 29 29 forearm Proximal reanastom
Morosetti, 2002 26 17 forearm Thrombectomy 
9 upper arm
Mickley, 2003 30 30 forearm Proximal reanastom
Ponikvar, 2005 268 . . . Thrombectomy 
Georgiadis, 2005 59 59 forearm Thrombectomy 
Palmar, 2006 10 3 forearm Thrombectomy
7 upper arm
Lipari, 2007 32 32 forearm Proximal reanastomanalysis can hardly been done.Recent studies report improved success rates of endovas-
cular intervention for thrombosed grafts that are comparable
with surgery. This may be attributed to better mechanical
devices and the administration of potent thrombolytics (tPA).
A major drawback is the high costs associated with the use of
mechanical devices.
The incident rate of thrombotic occlusion of autoge-
nous AVF is considerably lower compared with prosthetic
graft fistulae. In the past, less attention has been paid to the
management of thrombosed fistulae. Since 2000, an in-
creasing number of publications on endovascular and sur-
gical treatment have appeared in the literature.
Themechanism of thrombotic occlusion of the fistula is
a progressive stenosis, usually located at the site of the AV
anastomosis. In radiocephalic fistulae, side branches may
persist to drain the cephalic vein, even when thrombosis has
occurred at the anastomosis. A simple reanastomosis of the
cephalic vein to the more proximally located radial artery
Modality
Technical
success
Patency (1 yr)
Primary Secondary
bectomy 89% 32% . . .
n  urokinase 93% 49% 81%
9% 50%
bectomy 89% 27% 51%
bectomy  tPA 92% . . . . . .
kinase 93% 70% 80%
bectomy  urokinase, tPA 73% 24% 44%
bectomy 87% 23% . . .
n  tPA 87% 18% 69%
bectomy 96% 51% 84%
47% 62%
bectomy 76% 20% 54%
bectomy 96% 44% 89%
lity
Technical
success
Patency (1 yr)
Primary Secondary
80% 69% 89%
mal reanastomosis 82% 93% (6 mon) . . .
66% 84%
100% 80% 95%
mal reanastomosis 93% 75% 77%
interposition 95% . . . 85%
70% 51% 69
or graft interposition 84% 73% 88%hrom
iratio
hrom
hrom
 uro
hrom
hrom
iratio
hrom
hrom
hromoda
osis
proxi
osis
proxi
Graftcan salvage the access. The primary success rate of this
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higher compared with thrombectomy alone or combined
with graft interposition. Proximal reanastomosis can be
performed on an outpatient basis under local anesthesia.
The outcome of surgery for upper arm fistulae is worse
compared with forearm fistulae.
The primary success rates of endovascular treatment of
thrombosed fistulae are comparable with surgical revision.
Pharmacomechanical thrombolysis or mechanical throm-
bectomy alone yields similar outcome, with a90% clinical
success rate. One-year primary and secondary patencies are,
however, reduced compared with surgery. Tight stenoses,
usually at the AV anastomosis, may be resistant to angio-
plasty with conventional balloons (up to 12 atm), and
(ultra) high-pressure (to 32 atm) or cutting balloon angio-
plasty might be needed. A residual stenosis also may
progress in time and result in recurrent thrombosis.
The organization of an acute endovascular service with
the availability of trained interventionalists, experienced in
pharmacomechanical thrombectomy of vascular access, is a
prerequisite for good functional early and long-term pa-
tency. In addition, in those centers that lack adequate
endovascular services, timely access to the operating theater
is mandatory for surgical revision and salvage of the access.
Definitive randomized trials comparing endovascular
with surgical intervention for thrombosed autogenous fis-
tulae are desperately needed.
CONCLUSION
Endovascular and surgical intervention for thrombosed
dialysis prosthetic graft fistulae results in comparable early
success and long-term primary and secondary patency rates.
Surgery yields a better outcome for autogenous arterio-
venous fistulae, in particular in the long-term.
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